Gelesis HoldingsInc. logo

GLS

Gelesis HoldingsInc.

$0.44

Earnings Summary

Net Profits
$-14.26Mn

Highlights

Net Profits:

Gelesis HoldingsInc.’s net profit fell -25497.79% since last year same period to $-14.26Mn in the Q3 2021. On a quarterly growth basis, Gelesis HoldingsInc. has generated -248.63% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Gelesis HoldingsInc. post its latest quarter earnings

EPS Estimate Current Year
0

Highlights

EPS Estimate Current Year:

Gelesis HoldingsInc.’s earning per share (EPS) estimates for the current year stand at 0.

Key Ratios

Key ratios of the Gelesis HoldingsInc. post its Q3 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

Gelesis HoldingsInc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2022. This indicates that the Gelesis HoldingsInc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-11-14
0
0
NaN%

Company Information

Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its non-systemic superabsorbent hydrogels are the first and only made entirely from naturally derived building blocks, and they are inspired by the composition (i.e., water & cellulose) and mechanical properties (e.g., elasticity or firmness) of raw vegetables. They are conveniently administered in capsules to create a much larger volume of small, non-aggregating hydrogel pieces that become an integrated part of the meals, and act locally in the digestive system. Its portfolio includes Plenity®, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

Organisation
Gelesis HoldingsInc.
Headquarters
501 Boylston Street, Boston, MA, United States, 02116
Employees
101
Industry
Healthcare
CEO
Yishai Zohar

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*